Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells
Weber, R.; Weller, M.; Reifenberger, G.; Vasella, F.
Show abstract
The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) promoter region is a critical predictor of response to alkylating agents in glioblastoma. However, current approaches to study the MGMT status focus on analyzing models with non-identical backgrounds. Here, we present an epigenetic editing approach using CRISPRoff to introduce site-specific CpG methylation in the MGMT promoter region of glioma cell lines. Sanger sequencing revealed successful introduction of methylation, effectively generating differently methylated glioma cell lines with an isogenic background. The introduced methylation resulted in reduced MGMT mRNA and protein levels. Furthermore, the cell lines with MGMT promoter region methylation exhibited increased sensitivity to temozolomide, consistent with the impact of methylation on treatment outcomes in patients with glioblastoma. This precise epigenome-editing approach provides valuable insights into the functional relevance of MGMT promoter regional methylation and its potential for prognostic and predictive assessments, as well as epigenetic-targeted therapies.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- HiIDDD: A high-throughput imaging pipeline for the quantitative detection of DNA damage in primary human immune cells 93%
- PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma 93%
- Human HMGN1 and HMGN2 are not required for transcription-coupled DNA repair 93%
Similar papers in this journal
Similar papers in this journal
- 1--4-phenylpiperazine Treatment After Brain Irradiation Preserves Cognitive Function in Mice 94%
- Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials 92%
- Sirtuin 2 inhibition modulates chromatin landscapes genome- wide to induce senescence in ATRX-deficient malignant glioma 92%
Similar papers in this journal
- Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance 92%
- Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma 92%
- Hypoxia alters the effects of hypomethylating agents in acute myeloid leukaemia cells. 91%
Similar papers in this journal
- MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation 91%
- PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer 91%
- Heterogeneity of RNA editing in mesothelioma and how RNA editing enzyme ADAR2 affects mesothelioma cell growth, response to chemotherapy and tumor microenvironment 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.